AOTI, Inc.LSE: AOTI

AOTI: Directors'/PDMR Shareholding

· Issued by AOTI, Inc. via RNS

Summary by 6ix AI

On 4 November 2026, CSC Global bought AOTI, Inc. common shares on the London Stock Exchange for three persons discharging managerial responsibilities (senior managers whose share dealings are reported) under the company's Employee Share Purchase Plan. Participating employees' regular payroll contributions are used to buy the shares. AOTI, Inc. provides treatments for severe and chronic wounds.

Key details

  • Chief Executive Officer Mike Griffiths acquired 665 shares at £1.350 per share, for a holding after the purchase of 6,789,637 shares, or 6.38% of issued share capital.
  • Chief Financial Officer Jayesh Pankhania acquired 661 shares at £1.350 per share, for a holding after the purchase of 407,121 shares, or 0.38% of issued share capital.
  • Chief Operating Officer Anthony Moffatt acquired 660 shares at £1.350 per share, for a holding after the purchase of 1,182,487 shares, or 1.11% of issued share capital.

6ix AI wrote this summary from the release below and checked it against the release.

On 6ix: 6ix.com/news/directorspdmr-shareholding-7

Watch AOTI's latest callAoti (LSE:AOTI) — Half Year Results · Replay · Sep 30Read the transcript of Aoti (LSE:AOTI) — Half Year Results
AOTI, Inc.
04 November 2026
 

4 November 2026 


AOTI INC. (the "Company")

Directors'/PDMR Shareholding - Employee Share Purchase Plan

The Company was informed on 4 November 2026, that the following purchases of AOTI, Inc. common shares were made by CSC Global1 on 4 November 2026 on behalf of certain of the Company's persons discharging managerial responsibilities ("PDMR") pursuant to the Company's Employee Share Purchase Plan ("ESPP").

Under the ESPP, participating employees make regular payroll contributions which are used to acquire shares in the Company. Further information regarding the ESPP can be found in the announcement of 1 May 2026.

1CSC Global operates through CSC Employee Benefit Trustee (Jersey) Limited and CSC Employee Benefit Services (Jersey) Limited

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mike Griffiths

Jayesh Pankhania

Anthony Moffatt

2

Reason for the notification

a)

Position/status

1.   Chief Executive Officer

2.   Chief Financial Officer

3.   Chief Operating Officer

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

AOTI Inc.

b)

LEI

213800ZGCNDSTWIRK687

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Common shares of $0.00001 each

ISIN: US03690C1027

b)

Nature of the transaction

Purchase of common shares by the Trustee of the Employee Share Purchase Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Resultant shareholding post purchase

Resultant % of ISC post purchase

1.   £1.350p

2.   £1.350p

3.   £1.350

665

661

660

6,789,637

407,121

1,182,487

6.38%

0.38%

1.11%

d)

Aggregated information

- Aggregated volume

- Price

NA

NA

e)

Date of the transaction

4 November 2026

f)

Place of the transaction

London Stock Exchange

END

AOTI, INC.

Dr. Mike Griffiths, Chief Executive Officer

Jayesh Pankhania, Chief Financial Officer

+44 (0)20 3727 1000

ir@aotinc.net

Peel Hunt LLP (Nominated Adviser and Joint Broker)

Dr. Christopher Golden, James Steel

+44 (0)20 7418 8900

Panmure Liberum Limited (Joint Broker)

Emma Earl, Will Goode, Mark Rogers

Rupert Dearden

+44 (0)20 3100 2000

FTI Consulting (Financial PR & IR)

Ben Atwell, Simon Conway,

Natalie Garland-Collins

+44 (0)20 3727 1000

AOTI@fticonsulting.com

ABOUT AOTI, INC.

AOTI, INC. was founded in 2006 and is based in Oceanside, California, US and Galway, Ireland, providing innovative solutions that deliver outcome-based care and resolve severe and chronic wounds worldwide. Its products reduce healthcare costs and improve the quality of life for patients with these debilitating conditions. The Company's patented non-invasive Topical Wound Oxygen (TWO2®) therapy has demonstrated in differentiating, robust, double-blinded randomized controlled trials (RCT) and real-world evidence (RWE) studies to more-durably reduce the recurrence of Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88 per cent reduction in hospitalisations and 71 per cent. reduction in amputations over 12 months. TWO2® therapy can be administered by the patient at home, improving access to care and enhancing treatment compliance. TWO2® therapy has received regulatory clearance from the US (FDA), Europe (CE Mark), UK (MHRA), Health Canada, the Chinese National Medical Products Administration, Australia (TGA) and in Saudi Arabia. TWO2® therapy has also recently received positive coverage recommendations from the Federal Joint Committee (G-BA) in Germany and National Institute for Health and Care Excellence (NICE) in the United Kingdom. Also see www.aotinc.net

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

AOTI, Inc. on 6ix

Earlier from AOTI

All AOTI news releases